老年晚期上皮性卵巢癌治疗结局及预后分析

被引:5
作者
龙行涛
周琦
王海霞
王冬
邹冬玲
机构
[1] 重庆市肿瘤医院重庆市肿瘤研究所重庆市癌症中心妇科肿瘤科
关键词
老年; 卵巢肿瘤; 预后; 化学疗法;
D O I
10.19401/j.cnki.1007-3639.2017.08.010
中图分类号
R737.31 [卵巢肿瘤];
学科分类号
摘要
背景与目的:目前老年卵巢癌特别是晚期卵巢癌的治疗趋于保守,往往不能得到标准治疗,这方面的治疗经验及研究比较少。该研究旨在探讨老年晚期上皮性卵巢癌患者治疗结局、生存及影响预后相关因素。方法:回顾性分析重庆市肿瘤医院2008年4月—2012年12月收治的年龄大于等于65岁,Ⅲ、Ⅳ期上皮性卵巢癌患者临床资料,随访生存状况,分析影响预后的因素。结果:181例患者符合纳入标准,8.8%的患者未治疗,12.7%的患者接受单纯手术,15.5%的患者接受单纯化疗,33.2%的患者接受非标准治疗,29.8%的患者接受标准治疗。不同治疗方法基线比较,标准治疗组患者合并心脑血管疾病比例较低(P=0.001)。校正心脑血管合并症后,标准治疗组中位生存时间(48个月)、非标准治疗组中位生存时间(47个月)均明显长于其他组(P<0.001);单纯化疗组中位生存时间(26个月)明显长于单纯手术及未治疗组(P<0.001),而单纯手术组中位生存时间与未治疗组相似(9个月vs 8个月,P=0.269)。COX比例风险回归分析治疗方法、残余病灶大小、心脑血管合并症为影响卵巢癌预后的独立因素。结论:标准治疗仍是影响老年晚期上皮性卵巢癌患者预后的最重要因素。若患者不能耐受手术及术后辅助化疗,单纯化疗预后明显优于单纯手术,而单纯手术并不改善预后。
引用
收藏
页码:655 / 661
页数:7
相关论文
共 11 条
[1]   共病及共病指数研究进展与应用展望 [J].
周玉洁 ;
吕启圆 ;
李现文 .
中国公共卫生 , 2015, (11) :1513-1516
[2]   中国2003~2007年卵巢癌发病与死亡分析 [J].
杨念念 ;
严亚琼 ;
龚洁 ;
张思维 ;
郑荣寿 ;
陈万青 .
中国肿瘤, 2012, 21 (06) :401-405
[3]   Cancer Statistics, 2016 [J].
Siegel, Rebecca L. ;
Miller, Kimberly D. ;
Jemal, Ahmedin .
CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (01) :7-30
[4]  
Ovarian Cancer Treatment and Survival Trends Among Women Older Than 65 Years of Age in the United States; 1995–2008.[J].Jenny J. Lin;Natalia Egorova;Rebeca Franco;Monica Prasad-Hayes;Nina A. Bickell.Obstetrics & Gynecology.2016, 1
[5]   A preoperative personalized risk assessment calculator for elderly ovarian cancer patients undergoing primary cytoreductive surgery [J].
Barber, Emma L. ;
Rutstein, Sarah ;
Miller, William C. ;
Gehrig, Paola A. .
GYNECOLOGIC ONCOLOGY, 2015, 139 (03) :401-406
[6]   Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer [J].
Suidan, Rudy S. ;
Leitao, Mario M., Jr. ;
Zivanovic, Oliver ;
Gardner, Ginger J. ;
Roche, Kara C. Long ;
Sonoda, Yukio ;
Levine, Douglas A. ;
Jewell, Elizabeth L. ;
Brown, Carol L. ;
Abu-Rustum, Nadeem R. ;
Charlson, Mary E. ;
Chi, Dennis S. .
GYNECOLOGIC ONCOLOGY, 2015, 138 (02) :246-251
[7]   Risk stratification and outcomes of women undergoing surgery for ovarian cancer [J].
Patankar, Sonali ;
Burke, William M. ;
Hou, June Y. ;
Tergas, Ana I. ;
Huang, Yongmei ;
Ananth, Cande V. ;
Neugut, Alfred I. ;
Hershman, Dawn L. ;
Wright, Jason D. .
GYNECOLOGIC ONCOLOGY, 2015, 138 (01) :62-69
[8]  
Phase III SCORPION trial (ID number: NCT01461850) in epithelial ovarian cancer patients with high tumor load receiving PDS versus NACT: An interim analysis on peri-operative outcome.[J].A. Fagotti;G. Vizzielli;F. Fanfani;V. Chiantera;P.A. Margariti;V. Gallotta;B. Costantini;G. Ferrandina;L. Tortorella;G. Scambia.Gynecologic Oncology.2015,
[9]   Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: A meta-analysis [J].
Chang, Suk-Joon ;
Hodeib, Melissa ;
Chang, Jenny ;
Bristow, Robert E. .
GYNECOLOGIC ONCOLOGY, 2013, 130 (03) :493-498
[10]  
An analysis of patients with bulky advanced stage ovarian; tubal; and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).[J].Dennis S. Chi;Fernanda Musa;Fanny Dao;Oliver Zivanovic;Yukio Sonoda;Mario M. Leitao;Douglas A. Levine;Ginger J. Gardner;Nadeem R. Abu-Rustum;Richard R. Barakat.Gynecologic Oncology.2011, 1